Search tips
Search criteria 


Logo of gutGutView this articleSubmit a manuscriptReceive email alertsContact usBMJ
Gut. 1995 June; 36(6): 891–896.
PMCID: PMC1382628

Evaluation of intestinal permeability in patients with inflammatory bowel disease using lactulose and measuring antibodies to lipid A.


This study looked at the intestinal permeability and the immune response to enteric bacterial antigens in patients with inflammatory bowel disease (IBD). They were evaluated by using a lactulose tolerance test and measuring blood anti-lipid A antibody concentrations, respectively. The lactulose tolerance tests were performed 22 times in 14 patients with Crohn's disease (CD), 19 times in 12 patients with ulcerative colitis (UC), and 12 times in 12 healthy controls. Blood lactulose concentrations were measured after oral administration every two hours for eight hours, also blood C reactive protein concentrations and anti-lipid A antibody concentrations were measured just before lactulose administration. Blood lactulose concentrations were significantly higher in patients with CD than in the controls from two to eight hours after administration, while in UC they were significantly higher than in the controls from six to eight hours. Maximum blood lactulose concentrations in each tolerance test in patients with the active phase significantly exceeded those in the inactive phase of either CD or UC. A significant correlation was also seen between the maximum blood lactulose concentrations and the C reactive protein concentrations. Blood anti-lipid A antibody concentrations in patients with CD were significantly higher than in the controls as well as in patients with UC in immunoglobulin (Ig) A class and IgG class. In UC they were significantly higher than in the controls in IgA class. But, they were not related to the severity of the disease of either CD or UC, and not correlated significantly with the maximum blood lactulose concentrations in either CD or UC. The intestinal permeability and the immune response to enteric bacterial antigens in patients with inactive CD were significantly increased over those in the controls as well as in patients with inactive UC. These findings suggest that an increase of the intestinal permeability and that of producing antibodies to enteric bacterial antigens are both important for the pathogenesis of IBD, and that the characteristics of CD and UC differ.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.1M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Shanahan F. Pathogenesis of ulcerative colitis. Lancet. 1993 Aug 14;342(8868):407–411. [PubMed]
  • Jones VA, Dickinson RJ, Workman E, Wilson AJ, Freeman AH, Hunter JO. Crohn's disease: maintenance of remission by diet. Lancet. 1985 Jul 27;2(8448):177–180. [PubMed]
  • Scott MG, Nahm MH, Macke K, Nash GS, Bertovich MJ, MacDermott RP. Spontaneous secretion of IgG subclasses by intestinal mononuclear cells: differences between ulcerative colitis, Crohn's disease, and controls. Clin Exp Immunol. 1986 Oct;66(1):209–215. [PubMed]
  • Kett K, Rognum TO, Brandtzaeg P. Mucosal subclass distribution of immunoglobulin G-producing cells is different in ulcerative colitis and Crohn's disease of the colon. Gastroenterology. 1987 Nov;93(5):919–924. [PubMed]
  • MacDermott RP, Nash GS, Auer IO, Shlien R, Lewis BS, Madassery J, Nahm MH. Alterations in serum immunoglobulin G subclasses in patients with ulcerative colitis and Crohn's disease. Gastroenterology. 1989 Mar;96(3):764–768. [PubMed]
  • Sanderson IR, Boulton P, Menzies I, Walker-Smith JA. Improvement of abnormal lactulose/rhamnose permeability in active Crohn's disease of the small bowel by an elemental diet. Gut. 1987 Sep;28(9):1073–1076. [PMC free article] [PubMed]
  • Murphy MS, Eastham EJ, Nelson R, Pearson AD, Laker MF. Intestinal permeability in Crohn's disease. Arch Dis Child. 1989 Mar;64(3):321–325. [PMC free article] [PubMed]
  • Jenkins RT, Jones DB, Goodacre RL, Collins SM, Coates G, Hunt RH, Bienenstock J. Reversibility of increased intestinal permeability to 51Cr-EDTA in patients with gastrointestinal inflammatory diseases. Am J Gastroenterol. 1987 Nov;82(11):1159–1164. [PubMed]
  • Andre C, Descos L, Minaire Y. Comparison between lactulose-mannitol test and 51Cr-labelled ethylene diamine tetra-acetate test in inflammatory bowel diseases. Hepatogastroenterology. 1990 Dec;37 (Suppl 2):113–117. [PubMed]
  • Jenkins RT, Goodacre RL, Rooney PJ, Bienenstock J, Sivakumaran T, Walker WH. Studies of intestinal permeability in inflammatory diseases using polyethylene glycol 400. Clin Biochem. 1986 Oct;19(5):298–302. [PubMed]
  • Olaison G, Sjödahl R, Leandersson P, Tagesson C. Abnormal intestinal permeability pattern in colonic Crohn's disease. Absorption of low molecular weight polyethylene glycols after oral or colonic load. Scand J Gastroenterol. 1989 Jun;24(5):571–576. [PubMed]
  • Howden CW, Robertson C, Duncan A, Morris AJ, Russell RI. Comparison of different measurements of intestinal permeability in inflammatory bowel disease. Am J Gastroenterol. 1991 Oct;86(10):1445–1449. [PubMed]
  • O'Morain CA, Abelow AC, Chervu LR, Fleischner GM, Das KM. Chromium 51-ethylenediaminetetraacetate test: a useful test in the assessment of inflammatory bowel disease. J Lab Clin Med. 1986 Nov;108(5):430–435. [PubMed]
  • Almer S, Franzén L, Olaison G, Smedh K, Ström M. Increased absorption of polyethylene glycol 600 deposited in the colon in active ulcerative colitis. Gut. 1993 Apr;34(4):509–513. [PMC free article] [PubMed]
  • Hollander D. Crohn's disease--a permeability disorder of the tight junction? Gut. 1988 Dec;29(12):1621–1624. [PMC free article] [PubMed]
  • Hollander D. The intestinal permeability barrier. A hypothesis as to its regulation and involvement in Crohn's disease. Scand J Gastroenterol. 1992 Sep;27(9):721–726. [PubMed]
  • Kruis W, Schussler P, Weinzierl M, Galanos C, Eisenburg J. Circulating lipid A antibodies despite absence of systemic endotoxemia in patients with Crohn's disease. Dig Dis Sci. 1984 Jun;29(6):502–507. [PubMed]
  • Kamoi S. [Studies of antibodies to lipid A in patients with inflammatory bowel disease]. Nihon Shokakibyo Gakkai Zasshi. 1988 Jun;85(6):1245–1251. [PubMed]
  • MATTS SG. The value of rectal biopsy in the diagnosis of ulcerative colitis. Q J Med. 1961 Oct;30:393–407. [PubMed]
  • Fink PC, Galanos C. Determination of anti-lipid A and lipid A by enzyme immunoassay. Immunobiology. 1981;158(4):380–390. [PubMed]
  • Hendriksen C, Kreiner S, Binder V. Long term prognosis in ulcerative colitis--based on results from a regional patient group from the county of Copenhagen. Gut. 1985 Feb;26(2):158–163. [PMC free article] [PubMed]
  • Farmer RG, Whelan G, Fazio VW. Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis. Gastroenterology. 1985 Jun;88(6):1818–1825. [PubMed]
  • Binder V, Hendriksen C, Kreiner S. Prognosis in Crohn's disease--based on results from a regional patient group from the county of Copenhagen. Gut. 1985 Feb;26(2):146–150. [PMC free article] [PubMed]
  • Westphal O. Bacterial endotoxins. The second Carl Prausnitz Memorial Lecture. Int Arch Allergy Appl Immunol. 1975;49(1-2):1–43. [PubMed]
  • Shakib F, Stanworth DR. Human IgG subclasses in health and disease. (A review). Part II. Ric Clin Lab. 1980 Oct-Dec;10(4):561–580. [PubMed]

Articles from Gut are provided here courtesy of BMJ Publishing Group